A multicentric retrospective study assessing the efficacy of Brentuximab Vedotin in Μycosis Fungoides and Sezary Syndrome patients with variable CD30 positivity
Latest Information Update: 25 Jun 2021
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome
- Focus Therapeutic Use
- 25 Jun 2021 New trial record
- 16 Jun 2021 Results published in the British Journal of Dermatology